Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 3:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 3,229 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Solution Clear all
Completed Phase 1 Interventional

Bisphenol A Controlled Exposure Study

NCT01573429
View directory record Official record
Conditions
Healthy Volunteers
Interventions
deuterated-Bisphenol A (d-BPA)
Other
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
25 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 24, 2026, 3:23 AM EDT
Completed Phase 2 Interventional

Study to Assess the Safety and Efficacy of Benzocaine for Pain Relief in Children Presenting With Acute Otitis Media

NCT02092454
View directory record Official record
Conditions
Pain, Acute Otitis Media
Interventions
Benzocaine, Placebo
Drug
Lead sponsor
Otic Therapy, LLC
Industry
Eligibility
2 Months to 12 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Clearwater, Florida • Gresham, Oregon • Murray, Utah
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 24, 2026, 3:23 AM EDT
Completed Phase 3 Interventional

Early Re-Intervention Experiment 2

NCT01153594
View directory record Official record
Conditions
Substance Use Disorders
Interventions
Recovery Management Checkups (RMC)
Behavioral
Lead sponsor
Chestnut Health Systems
Other
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2010 · Synced Oct 24, 2026, 3:23 AM EDT
Withdrawn Not applicable Interventional

Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma

NCT00980551
View directory record Official record
Conditions
Retinoblastoma
Interventions
subtenon Carboplatin, Topotecan Hydrochloride, Vincristine, Filgrastim
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 24, 2026, 3:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

State Representation in Early Psychosis - Project 4

NCT05664594
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizoaffective Disorder
Interventions
Computerized Cognitive Training
Device
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 24, 2026, 3:23 AM EDT
Completed Phase 3 Interventional Results available

Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy

NCT02229539
View directory record Official record
Conditions
Acute Oral Mucositis Pain
Interventions
doxepin hydrochloride oral solution, DLA (diphenhydramine, lidocaine and antacids) rinse, Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
350
States / cities
Anchorage, Alaska • Burbank, California • Dublin, California + 221 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 24, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Results available

Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)

NCT01433731
View directory record Official record
Conditions
Lymphoma, T-Cell, Cutaneous
Interventions
placebo for SHAPE (SHP-141), SHAPE (SHP-141) 0.1% BID, SHAPE (SHP-141) 0.5% BID, SHAPE (SHP-141) 1.0% BID
Drug
Lead sponsor
TetraLogic Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Stanford, California • Chicago, Illinois • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Oct 24, 2026, 3:23 AM EDT
Withdrawn Phase 4 Interventional

Ketamine vs. Placebo as Adjunctive Therapies for Severe Alcohol Withdrawal

NCT02823977
View directory record Official record
Conditions
Alcohol Withdrawal
Interventions
Ketamine, Dexmedetomidine, Normal saline
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 24, 2026, 3:23 AM EDT
Not listed Early Phase 1 Interventional

Study Evaluating Efficacy of Topical Squaric Acid Dibutyl Ester in Children and Adolescents With Alopecia Areata

NCT05414266
View directory record Official record
Conditions
Alopecia Areata
Interventions
Placebo, SADBE 5%
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
12 Years to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 24, 2026, 3:23 AM EDT
Completed Phase 2 Interventional Results available

A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts

NCT03981822
View directory record Official record
Conditions
Condylomata Acuminata, Papillomavirus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Sexually Transmitted Diseases, Viral, Sexually Transmitted Diseases, Warts
Interventions
VP-102 and applicator, Placebo
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Plainfield, Indiana • Baton Rouge, Louisiana • Clarkston, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 24, 2026, 3:23 AM EDT
Not listed Phase 2 Interventional

A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy

NCT05488873
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
WST-057 Active, Placebo
Drug
Lead sponsor
WinSanTor, Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 24, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus

NCT02430870
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
TAK-648, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Anaheim, California • Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Oct 24, 2026, 3:23 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants

NCT02579265
View directory record Official record
Conditions
Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 Days
Interventions
Smoflipid 20% (investigational lipid for parenteral nutrition), Intralipid® 20%
Drug
Lead sponsor
Fresenius Kabi
Industry
Eligibility
0 Weeks and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
13
States / cities
Palo Alto, California • San Diego, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 24, 2026, 3:23 AM EDT
Completed Not applicable Interventional Results available

High-resolution, Relational, Resonance-based, Electroencephalic Mirroring (HIRREM) to Relieve Insomnia

NCT01971567
View directory record Official record
Conditions
Insomnia
Interventions
HIRREM
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 24, 2026, 3:23 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria

NCT03516487
View directory record Official record
Conditions
Phenylketonuria, Healthy
Interventions
SYNB1618, Placebo
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 64 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 24, 2026, 3:23 AM EDT
Recruiting Phase 2 Interventional

A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

NCT04042844
View directory record Official record
Conditions
Lumbar Disc Disease
Interventions
BRTX-100, Saline
Biological · Drug
Lead sponsor
BioRestorative Therapies
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Santa Monica, California • Walnut Creek, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 24, 2026, 3:23 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Increased Maternal Choline Intake on Child Cognitive Development

NCT04987099
View directory record Official record
Conditions
Pregnancy
Interventions
550 mg/day Choline, 25 mg/day Choline
Dietary Supplement
Lead sponsor
Cornell University
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 24, 2026, 3:23 AM EDT
Recruiting Phase 2 Interventional

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

NCT04469530
View directory record Official record
Conditions
Solid Tumor
Interventions
Sirolimus, Cyclophosphamide, Etoposide, Celecoxib
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Year to 30 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
5
States / cities
Atlanta, Georgia • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 24, 2026, 3:23 AM EDT
Completed Phase 3 Interventional

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

NCT00676507
View directory record Official record
Conditions
Lung Neoplasm, Carcinoma Non-small Cell Lung Cancer Stage IIIA, Carcinoma Non-small Cell Lung Cancer Stage IIIB, Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions
Lucanix™, Placebo Comparator
Biological · Other
Lead sponsor
NovaRx Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
53
States / cities
Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 24, 2026, 3:23 AM EDT
Completed Phase 4 Interventional Results available

Addition of Buprenorphine to Paracervical Block for Pain Control During Osmotic Dilator Insertion

NCT04254081
View directory record Official record
Conditions
Procedural Pain, Buprenorphine, Adjuvants, Anesthesia, Dilation and Evacuation, Analgesics
Interventions
Buprenorphine 0.15 MG, Lidocaine 1% Injectable Solution
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 24, 2026, 3:23 AM EDT
Completed Phase 1 Interventional

Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus

NCT02194400
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
RSLV-132
Biological
Lead sponsor
Resolve Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Clearwater, Florida • Grand Rapids, Michigan • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 24, 2026, 3:23 AM EDT
Completed Phase 3 Interventional Results available

Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays

NCT00279916
View directory record Official record
Conditions
Otitis Media, Serous, Negative Middle Ear Pressure, Rhinitis, Otitis Media With Effusion, Otitis Media, Secretory
Interventions
Triamcinolone acetonide nasal spray, Placebo nasal spray
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
6 Years to 100 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 24, 2026, 3:23 AM EDT
Completed Not applicable Interventional Results available

Metacognitive-Strategy Training in Sub-Acute Stroke

NCT04099511
View directory record Official record
Conditions
Stroke
Interventions
Usual Care Occupational Therapy-Outpatient, Cognitive Orientation to daily Occupational Performance
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
50 Years to 85 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 24, 2026, 3:23 AM EDT